Roth Capital Expects Weaker Earnings for Niagen Bioscience

Key Points

• Roth Capital has revised down its Q3 2025 earnings estimate for Niagen Bioscience to $0.00 per share from $0.01, while maintaining a "Buy" rating and a price target of $23.00.
• Niagen Bioscience reported earnings of $0.04 per share for Q2, exceeding the consensus estimate, with a revenue of $31.12 million, surpassing expectations of $28.55 million.
• Institutional ownership in Niagen Bioscience stands at 15.41%, with several investors recently increasing their stakes in the company.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Equities research analysts at Roth Capital reduced their Q3 2025 EPS estimates for Niagen Bioscience in a research note issued to investors on Thursday, August 7th. Roth Capital analyst S. Mcgowan now forecasts that the company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.01. Roth Capital has a "Buy" rating and a $23.00 price target on the stock. Roth Capital also issued estimates for Niagen Bioscience's FY2025 earnings at $0.08 EPS, FY2026 earnings at $0.13 EPS, Q2 2027 earnings at $0.07 EPS and FY2027 earnings at $0.26 EPS.

Other equities research analysts also recently issued reports about the stock. Canaccord Genuity Group upped their target price on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Wall Street Zen cut shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 2nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $13.22.

Niagen Bioscience Stock Performance

Shares of Niagen Bioscience stock traded up $0.12 on Friday, reaching $9.73. The company had a trading volume of 1,844,589 shares, compared to its average volume of 1,291,684. The firm's 50 day moving average price is $11.77 and its two-hundred day moving average price is $8.30. The firm has a market cap of $776.00 million, a PE ratio of 46.34 and a beta of 2.12. Niagen Bioscience has a 52-week low of $2.69 and a 52-week high of $14.69.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million.

Hedge Funds Weigh In On Niagen Bioscience

A number of large investors have recently bought and sold shares of NAGE. Tudor Investment Corp ET AL purchased a new position in shares of Niagen Bioscience in the 4th quarter valued at about $1,154,000. State of Tennessee Department of Treasury purchased a new position in Niagen Bioscience during the 4th quarter valued at about $140,000. XTX Topco Ltd purchased a new stake in shares of Niagen Bioscience during the fourth quarter worth about $120,000. Oxford Asset Management LLP purchased a new stake in shares of Niagen Bioscience during the fourth quarter worth about $151,000. Finally, Walleye Capital LLC purchased a new stake in shares of Niagen Bioscience during the fourth quarter worth about $215,000. Hedge funds and other institutional investors own 15.41% of the company's stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.